Funds and ETFs Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-05-28 EDT 5-day change 1st Jan Change
63.94 USD -2.65% Intraday chart for Gilead Sciences, Inc. -4.98% -21.07%

ETFs positioned on Gilead Sciences, Inc.

Name Weight AuM 1st Jan change Investor Rating
13.99% 254 M€ +12.51% -
8.10% 0 M€ 0.00% -
8.06% 0 M€ 0.00% -
5.23% 2 M€ -.--%
3.80% 7 M€ -.--% -
3.55% 1 M€ -0.95% -
2.90% 562 M€ -2.20%
2.66% 17 M€ +7.38% -
2.62% 458 M€ +1.41%
2.58% 6 M€ +6.17% -
2.27% 2 M€ 0.00%
1.67% 1 M€ +2.21% -
1.48% 9 M€ -4.31% -
1.26% 8 M€ +4.90%
1.26% 13,519 M€ +4.52%
1.23% 4,592 M€ +11.18%
1.21% 253 M€ +5.90%
1.16% 104 M€ +10.05%
1.04% 800 M€ +3.78%
1.01% 1,100 M€ +3.88%
1.00% 5 M€ -72.95% -
0.98% 3 M€ 0.00% -
0.96% 2 M€ +20.44% -
0.95% 9 M€ -.--% -
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.94 USD
Average target price
82.77 USD
Spread / Average Target
+29.46%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Funds and ETFs Gilead Sciences, Inc.